|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.56 USD | +3.36% |
|
+3.55% | +55.95% |
| Apr. 19 | Sector Update: Health Care Stocks Steady Pre-Bell Friday | MT |
| Apr. 19 | Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares | MT |
Spyre Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 0.886 million compared to USD 2.33 million a year ago. Net loss was USD 338.79 million compared to USD 83.82 million a year ago.
Basic loss per share from continuing operations was USD 49.12 compared to USD 24.86 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +55.95% | 1.35B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.87% | 22.15B | |
| -17.37% | 21.02B | |
| -8.24% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
SPYRE THERAPEUTICS, INC. 
